The pharmacological inhibition of USP7 has shown antitumor properties in several tumor types, including multiple myeloma [29], neuroblastoma [30], colon cancer [31], and lung neuroendocrine tumors [23]. This evidence concerns the gene USP7 and plasma cell myeloma.